Nanomerics

11 articles about Nanomerics

• Nanomerics Announces Ocular Molecular Envelope Technology (MET) Patent Granted in Canada

  4/13/2023

  Nanomerics Ltd., a private speciality pharmaceutical company announced that the Company had been granted patent protection in Canada for the ocular use of its Molecular Envelope Technology drug delivery system.

• Nanomerics Awarded an MHRA Innovation Passport for OC134

  8/31/2022

  Nanomerics Ltd., a private speciality pharmaceutical company, announced that the Company had received an Innovation Passport from the UK Medicines and Healthcare Products Regulatory Agency for its lead asset - OC134.

• Nanomerics CSO Made Honorary Fellow of the Royal Society of Chemistry

  7/20/2022

  Nanomerics Ltd., a private speciality pharmaceutical company, announced that the company's Chief Scientific Officer, Professor Ijeoma F. Uchegbu, had been made an Honorary Fellowship of the UK's Royal Society of Chemistry.

• Meet Nanomerics CSO in Montreal This Summer - Nanomerics CSO to Give Plenary Lecture at Controlled Release Society Annual Meeting and Expo in Montreal on 13th July 2022

  7/11/2022

  Nanomerics Ltd ., a private speciality pharmaceutical company, today announced that Nanomerics' Chief Scientific Officer would be giving a plenary lecture at the Controlled Release Society Annual Meeting and Expo on Wednesday 13th  July 2022. 

• Nanomerics Announces Quotient Sciences as its Clinical Trials Partner

  3/28/2022

  Nanomerics Ltd., a private speciality pharmaceutical company, announced that the Company had signed an agreement with Quotient Sciences, a drug development and manufacturing accelerator, for the delivery of its Sunlight Trial.

• Nanomerics Receives Further Upfront Payment for Anti-Viral Spray AnQlar(TM)

  3/22/2022

  Nanomerics Ltd., a private speciality pharmaceutical company, announced the receipt of a further milestone payment on agreeing the expansion of its anti-viral spray licence to Virpax Pharmaceuticals.

• Better Brain Medicines - Nanomerics Announces Patents Granted in the US, Europe and Japan on the Nose to Brain Use of its Molecular Envelope Technology

  3/14/2022

  Nanomerics Ltd., a private speciality pharmaceutical company, announced that the Company had been granted patent protection in multiple jurisdictions for brain delivery applications of its Molecular Envelope Technology.

• Nanomerics Expands and Moves to New Laboratories

  2/17/2022

  Nanomerics Ltd., a private speciality pharmaceutical company and University College London spin out, announced that the Company had invested significantly in its operations, and moved to new laboratories and offices in North London.

• 

  How Pharma and Academia are Tackling the Opioid Epidemic

  12/17/2021

  Deaths from drug overdoses have been on an upward trajectory for years, but have experienced a notable increase since the early days of the COVID-19 pandemic.

• Nanomerics announces patents granted in the US, Europe and Japan and two key publications on the ocular use of its Molecular Envelope Technology

  5/24/2021

  Nanomerics Ltd., a world leader in molecular engineered delivery technologies, announced the Company had been granted patent protection in multiple territories for the use of its Molecular Envelope Technology for ocular applications.

• NEMUS Bioscience Signs Development Agreement With Nanomerics To Advance Ocular Formulation Of NB1111 For The Treatment Of Glaucoma Using Proprietary Molecular Envelope Technology (MET)

  3/20/2017